Wall Street analyst estimates for Crinetics Pharmaceuticals, Inc. (CRNX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 13 |
| Hold | 8 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 21 |
| Avg rating (1-5) | 0.62 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-1.20 | ||
| 2026-08-03 | $-1.14 | $-1.18 | +3.4% |
| 2026-05-07 | $-1.23 | $-1.22 | -0.8% |
| 2026-02-26 | $-1.29 | $-1.37 | +5.8% |
| 2025-11-06 | $-1.38 | $-1.27 | -8.7% |
| 2025-08-07 | $-1.23 | $-1.13 | -8.8% |
| 2025-05-08 | $-1.04 | $-0.99 | -5.1% |
| 2025-02-27 | $-0.88 | $-0.92 | +4.3% |
Valuation Ratios
| Price / Book | 7.52 |
| EV / EBITDA | -17.68 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $589000 | $2.0M | $2.4M | $1.2M | $71000 | $1.1M | $4.7M | $4.0M | $1.0M | $7.7M |
| Cost of Revenue | $5.1M | $9.2M | $24.5M | $1.1M | $57.0M | 0 | 0 | 0 | 0 | $1.1M |
| Gross Profit | -$4.5M | -$7.2M | -$22.1M | $80000 | -$56.9M | $1.1M | $4.7M | $4.0M | $1.0M | $6.6M |
| Research & Development | $5.1M | $9.2M | $24.5M | $41.5M | $57.6M | $84.3M | $130.2M | $168.5M | $240.2M | $332.1M |
| Selling, General & Admin | $1.5M | $1.9M | $6.7M | $13.5M | $18.0M | $24.5M | $42.4M | $58.1M | $99.7M | $191.3M |
| Operating Expenses | $6.0M | $9.1M | $28.7M | $53.8M | $18.0M | $108.8M | $172.6M | $226.6M | $339.9M | $523.4M |
| Operating Income | -$6.0M | -$9.1M | -$28.7M | -$53.8M | -$75.0M | -$107.7M | -$167.9M | -$222.6M | -$338.9M | -$516.8M |
| EBITDA | -$6.0M | -$9.0M | -$28.2M | -$49.3M | -$74.0M | -$106.7M | -$162.9M | -$213.4M | -$295.6M | -$461.2M |
| Interest Expense | $11000 | $8000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$6.0M | -$9.2M | -$27.1M | -$50.4M | -$73.8M | -$107.6M | -$163.9M | -$214.5M | -$298.4M | -$465.1M |
| Income Tax | $10000 | -$40000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $180000 |
| Net Income | -$6.0M | -$9.2M | -$27.1M | -$49.5M | -$73.8M | -$107.6M | -$163.9M | -$214.5M | -$298.4M | -$465.3M |
| EPS | $-0.43 | $-0.66 | $-2.23 | $-2.05 | $-2.42 | $-2.80 | $-3.15 | $-3.69 | $-3.69 | $-4.95 |
| EPS (Diluted) | $-0.43 | $-0.66 | $-2.23 | $-2.05 | $-2.42 | $-2.80 | $-3.15 | $-3.69 | $-3.69 | $-4.95 |
| Shares Outstanding (Diluted) | $13.9M | $13.9M | $12.1M | $24.2M | $30.4M | $38.4M | $52.0M | $58.1M | $80.8M | $94.1M |
Price
| Price | $84.95 |
| Market Cap | $9.0B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACAD · AKRO · DYN · IMVT · KYMR · NAMS · PRAX
Explore sector: Healthcare · Biotechnology
More sections of CRNX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks